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PSA nadir as a predictive factor for biochemical disease-free
survival and overall survival following whole-gland salvage
HIFU following radiotherapy failure
TT Shah1,2, M Peters3, A Kanthabalan1,4, N McCartan1,4, Y Fatola1,4, J van der Voort van Zyp3, M van Vulpen3, A Freeman5, CM Moore1,4,
M Arya4, M Emberton1,4,6 and HU Ahmed1,4
BACKGROUND: Treatment options for radio-recurrent prostate cancer are either androgen-deprivation therapy or salvage
prostatectomy. Whole-gland high-intensity focussed ultrasound (HIFU) might have a role in this setting.
METHODS: An independent HIFU registry collated consecutive cases of HIFU. Between 2005 and 2012, we identiﬁed 50 men who
underwent whole-gland HIFU following histological conﬁrmation of localised disease following prior external beam radiotherapy
(2005–2012). No upper threshold was applied for risk category, PSA or Gleason grade either at presentation or at the time of failure.
Progression was deﬁned as a composite with biochemical failure (Phoenix criteria (PSA4nadir+2 ng ml− 1)), start of systemic
therapies or metastases.
RESULTS: Median age (interquartile range (IQR)), pretreatment PSA (IQR) and Gleason score (range) were 68 years (64–72),
5.9 ng ml− 1 (2.2–11.3) and 7 (6–9), respectively. Median follow-up was 64 months (49–84). In all, 24/50 (48%) avoided androgen-
deprivation therapies. Also, a total of 28/50 (56%) achieved a PSA nadir o0.5 ng ml− 1, 15/50 (30%) had a nadir ⩾ 0.5 ng ml− 1 and
7/50 (14%) did not nadir (PSA non-responders). Actuarial 1, 3 and 5-year progression-free survival (PFS) was 72, 40 and 31%,
respectively. Actuarial 1, 3 and 5-year overall survival (OS) was 100, 94 and 87%, respectively. When comparing patients with PSA
nadir o0.5 ng ml− 1, nadir ⩾ 0.5 and non-responders, a statistically signiﬁcant difference in PFS was seen (Po0.0001). Three-year
PFS in each group was 57, 20 and 0%, respectively. Five-year OS was 96, 100 and 38%, respectively. Early in the learning curve,
between 2005 and 2007, 3/50 (6%) developed a ﬁstula. Intervention for bladder outlet obstruction was needed in 27/50 (54%).
Patient-reported outcome measure questionnaires showed incontinence (any pad-use) as 8/26 (31%).
CONCLUSIONS: In our series of high-risk patients, in whom 30–50% may have micro-metastases, disease control rates were
promising in PSA responders, however, with signiﬁcant morbidity. Additionally, post-HIFU PSA nadir appears to be an important
predictor for both progression and survival. Further research on focal salvage ablation in order to reduce toxicity while retaining
disease control rates is required.
Prostate Cancer and Prostatic Diseases (2016) 19, 311–316; doi:10.1038/pcan.2016.23; published online 19 July 2016
INTRODUCTION
In the United Kingdom, every year up to one-quarter of men
diagnosed with prostate cancer undergo external beam radio-
therapy (EBRT).1 EBRT is an effective radical form of therapy;
however, similar to other therapies it can sometimes fail.
Approximately 1 in 4 to 1 in 3 develop biochemical failure. Of
these, it is estimated that up to 50% may have localised recur-
rence, which could be suitable for local salvage treatment.2–4
However, the majority receive androgen-deprivation therapy
(ADT) alone,3 which can confer systemic harms as well as cost,
especially when castrate resistance occurs after a median of
approximately 2–3 years.5,6
Local salvage treatment options include salvage radical
prostatectomy (SRP), cryotherapy, brachytherapy and high-
intensity focussed ultrasound (HIFU). These options could not
only provide a further curative strategy but defer the commence-
ment of ADT, which would in turn delay the onset of castrate
resistance and confer a cost beneﬁt.7–9 These salvage options
are at various stages of evaluation. We update our single-centre
experience of salvage whole-gland HIFU with medium-term
follow-up and aim to evaluate predictive factors for its success
or failure.
MATERIALS AND METHODS
Institutional review board exemption was granted by our local University
College London Hospital research and development committee. All
patients were placed in a prospectively maintained HIFU registry. Between
2005 and 2012, 50 consecutive men were identiﬁed who had undergone
whole-gland HIFU following histological conﬁrmation of localised disease
after prior EBRT. All underwent bone scan, pelvic/prostate multiparametric
magnetic resonance imaging (MRI) and cross-sectional computed tomo-
graphy (with or without choline or ﬂuorodeoxyglucose positron emission
tomography) to rule out metastases. No upper threshold was applied for
risk category, PSA or Gleason grade either at presentation or at time of
failure. Limited data were available on pre-EBRT characteristics including
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the radiotherapy dose despite approaching referring centres and was thus
not included in the statistical analyses.
All men underwent a standardised HIFU protocol:10 Patients were placed
in the lithotomy position with a Sonablate 500 device (Sonacare, Charlotte,
NC, USA) with a rectally placed treatment probe. Treatment planning took
place using the proprietary software and once started the software moved
the transducer automatically to allow complete coverage of the prostate.
Real-time ultrasound scanning was used to visualise the prostate during
treatment and power was adjusted according to changes seen. Acoustic
pulses measuring 3 × 3× 10 mm3 with slight overlap moved sequentially
through the prostate with 3 s ‘on’ time exposures and 6 s ‘off’ time
exposures. The prostate was divided into six blocks, left and right with
corresponding anterior, middle and posterior. A 4-cm focal length probe
was used for anterior and middle block treatment and a 3-cm probe for
posterior block treatment.
All patients had a suprapubic catheter placed postoperatively, with a
planned removal 2–6 weeks after treatment dependent on individual
patient urethral voiding function.
All were given aminoglycoside and cephalosporin antibiotics at
anesthetic induction and quinolone antibiotics for 7 days postoperatively.
Follow-up occurred with 3-monthly clinic visits in the ﬁrst year followed
by 6-monthly thereafter. Up to two salvage HIFU re-treatments were
permitted as part of the salvage strategy. PSA tests were performed at
these visits and patients were asked to complete patient-reported
outcome measures (PROM) questionnaires. Routine biopsies were offered;
however, no patient with a stable PSA opted for these and thus biopsies
were performed only if there was a rising PSA. In addition, patients with a
rising PSA were offered a multiparametric MRI prior to the biopsy.
Progression was deﬁned as a composite outcome of biochemical
recurrence using the Phoenix deﬁnition (PSA4nadir+2 ng ml− 1) or start of
ADT/second-line systemic treatments or development of metastases or
cancer-speciﬁc mortality.
Statistical analysis
Variables with a normal distribution are presented as mean (± s.d.), skewed
distributed variables as medians with interquartile ranges (IQR) and
categorical variables as absolute numbers with percentages. Kaplan–Meier
analysis was performed to assess the freedom from several outcomes:
biochemical failure, development of metastases, initiation of ADT, or a
combination of these three outcomes as a composite progression end
point. Statistical differences between subgroups were assessed with the
log-rank test. Determinants of the composite progression end point were
further analysed in univariable analysis with Cox-proportional hazards
regression. Hazard ratios with 95% conﬁdence intervals were obtained.
Factors taken forward into the multivariable analysis, that is, the nadir
value after salvage HIFU, were corrected for other determinants (with
Po0.25 from univariable analysis) to assess their independent value in
predicting the composite end point. Statistical signiﬁcance was set at
P⩽0.05. All analyses were performed using the R language environment
(version 3.1.2) for statistical computing (using the survival, rms and
survMisc packages).11
RESULTS
Pre-EBRT demographics
Limited data were available on the original diagnosis. Median Pre-
EBRT PSA was 17 ng ml− 1 (IQR 11–28.5) (available in 50%) and
median pre-EBRT Gleason score was 6 (range 4–8) (available
in 80%).
The treatment year for EBRT was available in 55% and this
ranged from 1996 to 2005 with the median year being 2002, while
radiotherapy dosing was available in only 27% and ranged from
50 Gy in 20 fractions to 72.5 Gy in 35 fractions with a median value
of 57.5 Gy.
Based on this information, the median disease-free survival
interval calculated from the date of original EBRT to the date of
salvage HIFU was 80 months (IQR 55–102).
Baseline pre-salvage HIFU demographics
Median age (IQR), median pretreatment PSA (IQR) and median
Gleason score (range) were 68 years (IQR 64–72), 5.9 ng ml− 1 (IQR
2.2–11.3) and 7 (82% were Gleason ⩾ 3+4, range 6–9), respectively.
In all, 33/50 (66%) had localised T1c–T2c disease while 17/50 (24%)
had radiological T3a/b disease. Median follow-up was 64 months
(IQR 49–84) (Table 1). Twenty (40%) underwent biopsies. These
were all non-protocol and were performed for either a rising PSA
or high posttreatment nadir. Also, 12/20 (70%) were positive for
signiﬁcant cancer (Gleason score ⩾ 7), 2/14 (%) were positive with
insigniﬁcant cancer (Gleason score = 6) and 6/20 (30%) were
negative.
Re-treatment occurred in 7/50 (14%) once and 2/50 (4%) had
two re-treatments. Six of these men had positive postsalvage HIFU
biopsies showing signiﬁcant cancer while 2 only had a rising PSA
and a multiparametric MRI showing residual disease but refused
conﬁrmatory biopsies prior to re-treatment. Their disease char-
acteristics on MRI matched the characteristics of the original
tumour and it was deemed to be residual cancer. The positive
predictive value for MRI also appears to be high in the post-HIFU
setting.12–16
Primary outcomes
Overall, 35/50 (70%) experienced biochemical failure, 26/50 (52%)
were started on ADT, 12/50 (24%) developed metastases and 9/50
(18%) died (cause of death was not available). Overall, composite
progression occurred in 38/50 (76%).
In all, 28/50 (56%) patients achieved a PSA nadir of
o0.5 ng ml− 1, 15/50 (30%) had a nadir ⩾ 0.5 ng ml− 1 and 7/50
(14%) did not achieve a nadir (PSA non-responders). Actuarial 1, 3
and 5 progression-free survival (PFS) was 72, 40 and 31%,
respectively (Figure 1). Analysis with PSA non-responders removed
resulted in 1-, 3- and 5-year actuarial PFS of 86, 47 and 37%,
respectively. Actuarial 1-, 3- and 5-year overall survival (OS) was
100, 94 and 87%, respectively (Figure 2).
Predictive factors
Univariable and multivariable Cox-regression analysis revealed
that the only signiﬁcant variable for either PFS or OS was
postoperative PSA nadir (Table 2). When comparing patients with
PSA nadir o0.5 ng ml− 1, nadir ⩾ 0.5 and non-responders, a
statistically signiﬁcant difference in PFS was seen (Po0.0001).
Three-year PFS in each group was 57, 20 and 0%, respectively
(Figure 3). Five-year OS was 96, 100 and 38%, respectively
(Figure 4).
Secondary outcomes
MRI outcomes. A total of 36/50 patients underwent a postsalvage
HIFU MRI to assess for any residual disease. In all, 10/36 (28%) had
a negative scan, 4/10 underwent conﬁrmatory biopsy and 2/4
(50%) were positive for signiﬁcant cancer. Also, 20/36 (56%) had a
Table 1. Descriptive statistics
Determinant Mean/median/n S.d./IQR/%
Age pre-HIFU, median, (IQR) 68 64–72
ADT use, N (%) 31 62%
PSA pre-HIFU, median, ng ml− 1, (IQR) 6.3 2.3–10.8
Nadir post-HIFU, median, ng ml− 1, (IQR) 0.12 0.05–0.83
No nadir after salvage HIFU, N (%) 7 15%
Progression (composite), N (%) 38 76%
BF, N (%) 35 70%
Metastases, N (%) 12 24%
Initiation ADT, N (%) 26 52%
Death, N (%) 9 18%
Abbreviations: ADT, androgen-deprivation therapy; BF, biochemical failure;
HIFU, high-intensity focussed ultrasound; IQR, interquartile range.
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Figure 1. Progression-free survival for the whole cohort of 50
patients.
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Figure 2. Overall survival for the whole cohort of 50 patients.
Table 2. Cox-regression analysis for composite end point/progression
Determinant Univariable (HR, 95% CI (P)) Multivariable (HR, 95% CI)
Age 0.94 (0.88–0.99 (P= 0.03)) 0.96 (0.90–1.01 (P= 0.13))
ADT 2.15 (1.06–4.37 (P= 0.04)) 1.69 (0.80–3.61 (P= 0.17))
PSA 1.00 (0.97–1.04 (P= 0.95)) —
PSA nadir
40.5 versus o0.5 2.63 (1.22–5.69 (P= 0.01)) 2.61 (1.19–5.73 (P= 0.02))
No nadir versus o0.5 35.11 (10.64–115.81 (Po0.0001)) 28 (8.29–94.53 (Po0.0001))
NCCN risk group (high versus intermediate) 1.22 (0.62–2.40 (P= 0.57)) —
Abbreviations: ADT, androgen-deprivation therapy; CI, conﬁdence interval; HR, hazard ratio; NCCN, National Comprehensive Cancer Network.
Figure 3. Progression-free survival by nadir status.
Figure 4. Overall survival by nadir status.
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positive scan and conﬁrmatory biopsy was positive in all 9/9
patients who underwent it. The remaining 6/36 (17%) had either
an equivocal result or images were not suitable for analysis; 2/6
underwent biopsy and these were negative in both.
Functional outcomes. Twenty-nine patients completed PROM
questionnaires. Three patients had preexisting pad usage, and
thus with their data removed, patient-reported urinary incon-
tinence (any pad-use) was 8/26 (31%). Symptoms of bladder outlet
obstruction were common and intervention in the form of a
bladder neck incision, transurethral resection or urethral dilatation
was needed in 27/50 patients (54%). Reviewing their results
showed that they were no more likely to report incontinence than
those who did not undergo intervention.
When assessing International Index of Erectile Function (IIEF)-15,
although 29 patients returned at least one questionnaire
only 13 patients returned both one preoperative and one post-
operative questionnaire. Reviewing only the results for these
patients demonstrated that the majority had preexisting severe
erectile dysfunction with a pretreatment median IIEF-15 score of 9
(mean= 15.3). Over a 12-month follow-up period, there was a non-
signiﬁcant median 3-point (mean 7 point) drop in IIEF-15 score.
Early in the learning curve, between 2005 and 2007, 2/41
developed a recto-urethral ﬁstula after one salvage HIFU; a further
1/9 developed a ﬁstula after a redo-HIFU. Overall, 3/50 (6%)
developed a ﬁstula. Two were managed with a diversion or
closure along with an SRP while one was managed conservatively.
In addition, 3/50 (6%) developed osteonecrosis of the pubic
symphysis needing prolonged antibiotic treatment.
DISCUSSION
Summary
Our results demonstrate a relatively low 5-year PFS of 31%,
although OS was high with 87% of men still alive after 5 years.
This decreased to 64% at 8 years but is comparable to the
survival outcomes of patients undergoing SRP.17 Our results also
highlight the discrepancy between disease progression, largely
deﬁned by biochemical failure, and survival. It must be noted that
we had very few selection criteria for patients undergoing salvage
HIFU. In patients who obtained a nadir of o0.5 ng ml− 1, 3-year
PFS was 57% compared with 20% in those with a nadir
40.5 ng ml− 1 or 0% in non-responders. Side effects within
our series were also high as with other salvage therapies in this
high-risk group.
Limitations
First, our sample size was relatively small, hence reducing the
power of the statistical and multivariable analyses. Also owing to
lack of data from initial diagnosis including radiotherapy dose, we
were unable to use these parameters in our analysis. Second, it is
possible that the true incontinence and erectile dysfunction rates
may differ as we had incomplete PROM data in 42% of patients.
However, our ﬁgures appear comparable to results from larger
studies such as by Murat et al.18 and Crouzet et al.19 and the use of
validated patient self-reported questionnaires does add a degree
of validity to our results. Third, there is no PSA criteria that has
been validated in this salvage setting to deﬁne biochemical
failure. In our study, we used the Phoenix criteria as the majority of
patients had failed EBRT based on this criterion that is the most
commonly used deﬁnition in studies assessing minimally invasive
salvage therapies. In addition, we used a more expansive
composite outcome to deﬁne failure, which included not only
clinical progression, that is, metastases/death but also clinician-
determined need for initiation of second-line treatments, regard-
less of PSA failure, such as ADT. Thus our PFS outcomes may seem
higher than studies that have only reported biochemical disease-
free survival. Fourth, not all patients underwent conﬁrmatory
post-HIFU biopsy. In an ideal study, all patients would undergo
posttreatment biopsies. Although we offered all patients biopsy,
our data mirrors practice where patients with a stable PSA tend to
refuse biopsy and even a proportion of patients with clinical
suspicion for recurrence choose not to undergo biopsy and rather
opt for continued PSA surveillance or proceed directly to next line
treatment, that is, hormones. Furthermore, some patients devel-
oped metastases on re-staging scans and thus biopsies in these
patients was deemed unnecessary. Finally, cause of death was not
available, although it is likely that many of these were prostate
cancer related as 5/9 had developed metastases while 3/9 patients
had biochemical failure only and 1/9 had no evidence of
progression.
Clinical implications
Treatment options for patients with radio-recurrent disease are
limited and historically have consisted of observation, ADT or SRP.
SRP is a potentially curative procedure but is technically
challenging owing to radiation-induced ﬁbrosis and obliteration
of tissue planes. Oncological outcomes range from a biochemical
PFS of 47–82% at 5 years and OS of 54–89% at 10 years. However,
complications are common with a 0–43% transfusion rate, erectile
dysfunction in 80–100%, incontinence in 21–90%, anastomotic
stricture in 7–41% and rectal injury in 0–28%.17,20
Minimally invasive therapies are currently under evaluation,
including brachytherapy, cryotherapy and HIFU. Our results are in
keeping with previously published larger whole-gland salvage
HIFU series by Murat et al.18 and Crouzet et al.19 consisting of 167
and 290 patients, respectively. Murat et al.18 initially reported a
3-year PFS of 53, 42 and 25% for (D’Amico) low, intermediate and
high-risk patients, respectively, with a 5-year OS of 84%.
Subsequently, Crouzet et al.19 reported 5-year PFS rates of 45,
31 and 21% for D’Amico low-, intermediate- and high-risk prostate
cancer, respectively, and a 7-year cancer-speciﬁc survival of 79.6%.
However, unlike these studies we did not ﬁnd, after univariable
and multivariable analysis, that any pretreatment variable were
predictors of either progression or survival. In our series, only
postoperative PSA nadir was seen to be a strong predictor and
patients with a nadir40.5 ng ml− 1 (or PSA non-responders) had a
poorer prognosis when compared with patients with PSA nadir
o0.5 ng ml− 1. These ﬁndings could be due to the smaller sample
size in our series or they may represent the difﬁculty in accurate
risk stratiﬁcation after radiotherapy and the inability of current
imaging modalities to detect micrometastases that have a high
prevalence in this group of men.21,22 We estimate that 30–50% of
men may harbour micrometastases at presentation with recur-
rence. This is based on the fact that, even in the presence of local
treatment such as salvage prostatectomy, 10-year biochemical
and metastases-free survival can be as low as 28% and 77%,
respectively.17,23
Unfortunately, similar to SRP, the poor side effect proﬁle for
whole-gland salvage HIFU has limited its use and recent work has
focussed on focal therapy of the recurrence. The aim of a tissue-
preserving strategy is to achieve similar oncological outcomes by
treating only the area of recurrence but with a signiﬁcantly
improved side effect proﬁle. This would be in keeping with the
evidence that the site of recurrence is usually related to the
location of the original tumour or ‘index’ lesion.24 Our group has
previously reported on 39 patients undergoing focal salvage HIFU.
The early oncological outcomes seem comparable with a 1- and
2-year PFS of 69% and 49%, respectively. Side effects also appear
to be lower than whole-gland salvage HIFU: 87% were pad-free,
23% needed intervention for bladder outﬂow obstruction, and
2.6% had a ﬁstula after one salvage focal HIFU and 0% after a
redo-HIFU.25 In addition, there is encouraging data from the focal
salvage cryotherapy registry showing 1-, 3- and 5-year baseline
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disease-free survival of 95.3, 72.4 and 46.5%, respectively, with
associated low rates of incontinence (5.5%), erectile function
(50%) and ﬁstulae (3.3%).26
It is evident that further research is required. Although
comparative effectiveness trials are ideal, a recent randomised
controlled trial of whole-gland salvage cryotherapy versus watch-
ful waiting ±ADT failed to accrue.27 We have since started
recruiting into a study (FORECAST, NCT01883128, UKCRN15936)
that aims to prospectively assess 177 patients for radiorecurrent
prostate cancer initially with bone scintigraphy, positron emission
tomography–computed tomography, whole-body MRI and tem-
plate mapping biopsies with subsequent salvage focal ablation
with HIFU or cryotherapy in those with suitable parameters.28 In
addition to the side effect proﬁle, another beneﬁt of focal ablation
may be an anticancer immune response, and within FORECAST,
patients with oligometastatic disease will be offered ‘cytoreduc-
tive’ focal therapy with local salvage treatment in addition to
ADT.29
With reference to the learning curve, Rébillard et al.30 in 2003
commented on a learning curve of 10–15 cases. We are not aware
of any more recent evidence in the literature regarding the
learning curve for prostate HIFU in its current form. Over the past
10 years, HIFU has developed from early stage 1 toxicity studies
into large prospective stage 2b series/trials assessing efﬁcacy.
Progression through these stages has allowed development and
reﬁnement of both the technique and the equipment. We have
yet to deﬁne a learning curve for this complex procedure but
certainly it should be coached in expert centres who have
extensive experience of primary HIFU.
CONCLUSION
Whole-gland salvage HIFU carries signiﬁcant morbidity. In our
series of high-risk patients, in whom we estimate, based on the
literature, that 30–50% may have micro-metastases at the
time of presentation, disease control rates were promising in
PSA responders.17,21–23,31 Furthermore, PSA nadir after treat-
ment appears to be an important predictor for both progression
and survival. Further research on focal salvage ablation as a
strategy to reduce toxicity while retaining disease control rates is
required.
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